Mount Sinai Researchers Identify Mechanisms That Are Essential for Proper Skin Development
Latest discovery could improve development of future stem cell therapies and cancer treatments
Mount Sinai researchers have discovered that Polycomb complexes, groups of proteins that maintain gene expression patterns, are essential for proper skin development, according to a paper published in Genes & Development on February 18. This latest discovery could improve development of future stem cell therapies to generate “skin on a dish” to transplant into burn victims and patients with skin-blistering disorders.
Polycomb complexes are groups of proteins that maintain the gene-expression patterns during early development by regulating the structure of DNA and proteins in cells. They play a critical role in the repression of gene expression, or the switching-off of individual genes to help control responses to changing environments and stimuli. The researchers found that Polycomb repressive complex 1 (PRC1) and Polycomb repressive complex 2 (PRC2) each help maintain the skin-specific gene expression pattern necessary for proper development of the skin.
The researchers studied Polycomb complexes in the developing skin of mice. Mice that were bred missing either Polycomb complex still had a functioning skin barrier, albeit with minor defects in skin thickness. In contrast, when researchers bred mice missing both complexes, it resulted in severe skin defects including a significantly thin epidermis that lacked essential layers required for survival. The researchers found that PRC1 and PRC2 help maintain regular function of gene repression, in particular the repression of transcription factors essential for the formation of non-skin tissues.
“We show that Polycomb complexes function redundantly to control proper development of the skin,” said the study’s corresponding author Elena Ezhkova, PhD, Professor of Cell, Developmental and Regenerative Biology, and Dermatology in the Black Family Stem Cell Institute at the Icahn School of Medicine at Mount Sinai. “Polycomb complexes function together to repress non-skin lineage programs and thus control proper skin development.”
The researchers said their discovery has implications for development of stem cell therapies to produce “skin on a dish” to use for transplantation. Since Mount Sinai researchers have established that both Polycomb complexes are vital for skin formation, this discovery could improve current protocols for generating skin cells from stem cells. Polycomb complexes are also often overexpressed in epithelial cancers, including skin cancers, and treatments using Polycomb inhibitors are currently being studied in clinical trials. This study suggests that parallel inhibition, use of both PRC1 and PRC2 inhibitors, may be a more powerful form of treatment for cancer patients.
While Polycomb complexes are important for skin function, their role in other tissues remains unknown. Future studies should explore the role of Polycomb complexes in developing and regenerating tissues, the researcher said.
This research was supported by the National Institutes of Health. The Albert Einstein College of Medicine and RIKEN Center for Integrative Medical Sciences in Japan contributed to the study.
About the Mount Sinai Health System
Mount Sinai Health System is one of the nation’s leading integrated academic health systems and one of the largest in the New York metropolitan area. Its comprehensive system includes seven hospitals, more than 400 outpatient practices, over 600 research and clinical laboratories, the Icahn School of Medicine at Mount Sinai, the Graduate School of Biomedical Sciences, and the Mount Sinai Phillips School of Nursing. Together, the Health System comprises approximately 48,000 employees, more than 9,000 physicians, and 8,600 nurses.
As a leading learning health system, Mount Sinai combines clinical expertise with scientific discovery to improve patient care while training the next generation of health care and biomedical leaders. The Health System provides care across every stage of life, from prenatal care through geriatrics, while advancing personalized medicine through artificial intelligence, data science, and biomedical research.
Mount Sinai is consistently recognized among the nation’s leading academic health systems for patient care, research, and education. The Mount Sinai Hospital is ranked No. 1 in New York by Newsweek and No. 5 on the magazine’s World’s Best Hospitals list. The Icahn School of Medicine at Mount Sinai ranks No. 11 among U.S. medical schools and No. 1 among freestanding medical schools for National Institutes of Health funding, reflecting the strength of its scientific enterprise and leadership in biomedical research.